Cambrian Bioworks raised $1.45 million in seed funding led by the Irani family office to improve its automated molecular diagnostics platforms and expand globally.
Founded in 2020, the Bengaluru-based startup develops automated platforms used in oncology, genomics, and disease testing.
With the recent launch of Manta, their nucleic acid extraction device, Cambrian Bioworks plans to extend its reach by enabling broader access to automated devices for liquid biopsy testing,
Biotechnology startup Cambrian Bioworks has secured $1.45 Mn (INR 12 Cr) in a seed funding round led by the Irani family office, along with participation from the company’s cofounder and CEO Vaibhav Hegde.
The Bengaluru-based startup plans to use the fresh capital to scale up its automated molecular diagnostics platforms, bolster R&D efforts, expand team and support international market expansion.
Founded in 2020, by Vaibhav Hegde, Rohit Asil and Raghav Sridhar, Cambrian Bioworks builds automated molecular diagnostic platforms.
The company’s products find applications in oncology, genomics, rare disease testing, and AMR detection. It builds tools for advanced DNA sequencing and molecular diagnostic markets.
“Molecular diagnostics is crucial for precise diagnosis, disease subtyping, and therapy selection in cancer care. This funding marks a significant milestone in our journey.” Hegde said.
(The story will be updated soon)
